A Multi-center Double Blind Placebo Controlled Study to Assess the Safety and Efficacy of TB006 for Improving Core Symptoms in Adults With Autism Spectrum Disorder

Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.

Start Date03 Aug 2024

Sponsor / Collaborator-

NCT05476783 / Active, not recruitingPhase 2

A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Start Date14 Sep 2022

Sponsor / Collaborator

TrueBinding, Inc.Startup

NCT05156827 / WithdrawnPhase 2

A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke

This multi-center, randomized, parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of TB006 in participants with an Acute Ischemic Stroke (AIS) event with 57 days of treatment.

Start Date26 Jul 2022

Sponsor / Collaborator

TrueBinding, Inc.Startup

100 Clinical Results associated with TB-006

100 Translational Medicine associated with TB-006

100 Patents (Medical) associated with TB-006

Literatures (Medical) associated with TB-006

01 May 1951·Zeitschrift fur Laryngologie, Rhinologie, Otologie und ihre Grenzgebiete

[Treatment of laryngeal tuberculosis with conteben, with Tb 6, streptomycin and PAS].

Article

Author: WOLF, H E

News (Medical) associated with TB-006

28 Mar 2023

·healthcare-digital.com

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Alzheimer’s Disease Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more An estimated one in nine people suffer from Alzheimer’s Disease, according to the Alzheimer’s Association. The disease wrecks an individual memory and ability to think, eventually preventing them from doing minor tasks. As the population of older-adults increases, research is being undertaken to learn more about the devastating disease and how to fight it. Doctor Sun leads a team of scientists with multiple disciplines to develop novel, first-in-class antibody drugs to treat neurologic disorders, including Alzheimer’s Disease, stroke, metabolic diseases like diabetes, fibrotic diseases like NASH, kidney failure, and cancers. “After finishing my undergraduate and graduate studies in China, I obtained my PhD from the University of Minnesota studying innate immunity,” said Doctor Sun. “I then conducted my postdoctoral research at Cornell University Medical College to elucidate a new signal transduction pathway for inflammatory cytokine of interferon gamma in macrophages.” Before founding TrueBinding, Doctor Sun was in research. When he met an investor who had the same goal to create innovative treatments in 2015, he used the opportunity to set up TrueBinding. TrueBinding’s mission: to discover new drug targets TrueBinding’s research is around tumours, fibrotic diseases, metabolic diseases, autoimmune diseases and neurologic diseases. “TrueBinding is a technique platform to discover novel drug targets,” explains Doctor Sun. “Through my research career, I developed a unique, powerful technique to discover true binding partners for a known protein. For example, PD-1 is a checkpoint regulator expressing on T cells to suppress immune reaction. Tumour expresses its binding partner, PD-L1, to evade immune attack. Since PD-1 and PD-L1 interaction was known, a PD-1 antibody blocking the interaction can reactivate immune reaction to kill tumours. When we first started the company, I used the platform to find Galectin-3 as a true binding partner for Tim-3, a well-known negative checkpoint regulator of T cell activation.” As mentioned, Galectin-3 is the first drug target the company discovered. “Indeed, this molecule was reported to be highly involved in many diseases listed in the question. Therefore, its blocking antibodies have shown great efficacy in the animal models of these diseases.” Doctor Sun Dongxu Sun , CEO at TrueBinding Inc TrueBinding’s antibody drug development Besides the drug target discovery platform, TrueBinding has also built other platforms essential for antibody drug development, including: Target validation Antigen immunisation and monoclonal antibody production Antibody engineering Antibody lead selection and validation Toxicological studies Manufacturing and clinical trials “Our clinical lead antibody TB006 in a completed phase 2a trial in Alzheimer’s disease showed a trend of disease reversal after only one month of treatment,” explains Doctor Sun. Over the next year, TrueBinding has plans for more clinical trials and purposes for its data. “Longer treatment in the ongoing open label extension study in Alzheimer’s disease is generating more convincing data of disease reversal even in severe patients so we hope to pass the new hope to the Alzheimer’s disease community and the public,” says Doctor Sun. “Next year with more data accumulated from this study, we will have a better picture regarding the extent to which the treatment might reverse the disease. “In the summer of this year, a new phase 2b with one year treatment will be initiated and our hope is that by next year it can be finished. Our hope and expectation is that it will produce strong clinical data. We also have one ongoing stroke clinical study and hope to get positive data next year when it is finished. As mentioned, we have preclinical data for Parkinsons, Epilepsy and type II diabetes so next year those clinical trials can be initiated too.”

Phase 2

28 Mar 2023

·www.biospace.com

Open-Label Extension Study for Alzheimer's Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months

FOSTER CITY, Calif., March 28, 2023 /PRNewswire/ -- TrueBinding, Inc.— a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and other disease areas with great unmet needs— today announced early results from an Open-Label Extension (OLE) study for the use of its TB006 drug in the treatment of Alzheimer's Disease. The early results indicate the potential for the reversal of disease progression and sustained clinical benefits beyond the drug's phase 2a clinical trial success. "The one-month treatment of Alzheimer's Disease with TB006 in the blinded phase 2a trial yielded strong clinical data pointing to a trend of disease reversal in moderate to severe cases, but Alzheimer's Disease is a chronic disease, so some people may require longer treatment to show improvement," said Dr. Dongxu Sun, Ph.D., Chief Executive Officer of TrueBinding and an expert in the development of novel drugs, adding that this was one of the primary motivations behind the OLE study. "A significant number of participants in the OLE study, including those with severe Alzheimer's Disease, have shown disease reversal or stabilization after only three months of treatment, and without significant adverse events." Among 79 participants who completed a three-month treatment in the OLE study, 47 percent showed signs of disease reversal or cognitive improvement and 28 percent showed disease stabilization. This means that the majority of participants experienced a positive response. This is a significant improvement over results from other treatments currently on the market for Alzheimer's Disease. According to Sun, Lecanemab— a treatment not affiliated with TrueBinding— which received accelerated approval from the FDA in January 2023, showed zero signs of disease reversal or improvement after 18 months of treatment. TB006's outcomes suggest that the drug may be an effective treatment option for Alzheimer's Disease beyond what is currently available. The OLE study expands upon the work already completed in clinical trials. Results from TrueBinding's phase 2a clinical trial were released in November 2022. The results of that study indicated that the drug improved cognition and function in study participants with moderate to severe Alzheimer's Disease with little to no side effects. This prompted the science team to initiate an OLE study to pursue additional data on the drug's long-term benefits and safety profile. "The biggest benefit to an Open-Label Extension study is obtaining long-term safety data," said Sun. "And it is our hope that a longer treatment in the OLE will yield strong, sustained clinical benefits." The uncontrolled OLE study commenced in September 2022 and will follow participants for up to two years to collect and report on general observations. TrueBinding will also soon commence a phase 2b study, which will collect and analyze additional clinical data over the course of a full year. Sun said that the company hopes and expects that the OLE study results and the phase 2b clinical trial "will reveal more about the potential for use of TB006 in treating Alzheimer's Disease." TrueBinding will attend a Type B End-of-Phase 2 meeting with the FDA in April 2023 to discuss the results of the phase 2a clinical trial and updated results from the OLE study, and the potential for a rapid development pathway for TB006. About TB006 TB006 is a humanized monoclonal antibody that, by blocking Galectin-3, the root cause of neuroinflammation and aggregation of Aβ and pTau and other pathogenic factors, has the potential to improve cognition and functioning of patients with Alzheimer's disease (AD). In AD in vivo model studies, TB006 showed promising capabilities in significant reduction of the aggregation of Aβ/Tau proteins and neuroinflammation, and significant improvement of cognitive performance. In a Phase 1b/2a proof-of-concept trial in mild to severe AD patients, TB006 demonstrated great improvements in cognition and functioning. TB006 is currently being evaluated in a Phase 2 open-label extension trial in patients with AD and in a Phase 2 trial in patients with acute ischemic stroke. About TrueBinding, Inc. TrueBinding Inc. is a clinical-stage biotherapeutics company focused on pioneering the development of innovative monoclonal antibodies for the treatment of some of the most challenging neurodegenerative diseases, including Alzheimer's disease (AD), as well as stroke, oncology and other serious diseases. For more information, visit . Contacts: Camille Dawson 315-323-7545 356204@email4pr.com

Phase 2Clinical Result

27 Feb 2023

·www.prnewswire.com

DelveInsight Evaluates a Robust Alzheimer's Disease Pipeline as 150+ Influential Pharma Players to Set Foot in the Domain

LAS VEGAS, Feb. 27, 2023 /PRNewswire/ -- The prevalence of Alzheimer's disease has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of Alzheimer's disease and the growing research and development activities to develop novel therapies to treat Alzheimer's disease to drive the market. The companies developing the potential therapies in the last stage of development include Eli Lilly and Company, AB Sciences, AZTherapies, and several others. DelveInsight's ' Alzheimer's Disease Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline Alzheimer's disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Alzheimer's disease pipeline domain. Key Takeaways from the Alzheimer's Disease Pipeline Report DelveInsight's Alzheimer's disease pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Alzheimer's disease treatment. Key Alzheimer's disease companies such as Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others are evaluating new Alzheimer's disease drugs to improve the treatment landscape. Promising Alzheimer's disease pipeline therapies in various stages of development include ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121, LX1001, TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx, Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916, AR1001, ORY-2001, LY3372689, MW150, EX039, SLS-005, Seltorexant, Donanemab, SHR-1707, REM0046127, ALZ-101, VT301, NE3107, PRX005, MK-6240, and others. In February 2023, Lantheus Holdings, Inc. announced it had acquired Knoxville-based Cerveau Technologies, Inc. ("Cerveau"). Cerveau's asset is MK-6240, a second-generation F 18-labeled positron emission tomography ("PET") imaging agent that targets Tau tangles in Alzheimer's disease.Under the terms of the agreement, Lantheus will pay an upfront payment and potential additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales. In January 2023, Prothena Corporation plc announced positive topline Phase I single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer's disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. The results of the study found all three dose level cohorts of PRX005 to be generally safe and well tolerated, meeting the Phase 1 SAD study primary objective. None of the treatment emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters. PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints. In January 2023, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the accelerated approval submission of donanemab for the treatment of early symptomatic Alzheimer's disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission. No other deficiencies in the application were noted.The confirmatory Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with topline data read-out expected in Q2 2023, and will form the basis of donanemab's application for traditional approval shortly thereafter. Lilly will continue to work with the FDA to evaluate the fastest pathway to make this potential treatment option widely available to patients. In January 2023, Coya Therapeutics, Inc. announced the recent publication of an article entitled "Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's Disease" in the peer-reviewed journal Acta Neuropathologica Communications.Furthermore, Treg-treated mice showed a significant reduction in total and plaque-associated microglia as well as reactive astrocytes in the dentate gyrus and frontal cortex versus untreated mice. The reduction in the number of plaque-associated glial cells and suppression of pro-inflammatory signaling pathways within these cells following Treg therapy may attenuate the contribution of these toxic glial cells in AD pathology resulting in mitigation of amyloid burden. In November 2022, Eli Lilly and Company announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase III TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies. Donanemab is an investigational antibody that targets a modified form of beta-amyloid plaque called N3pG. Request a sample and discover the recent advances in Alzheimer's disease drug treatment @ Alzheimer's Disease Pipeline Report The Alzheimer's disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Alzheimer's disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Alzheimer's disease clinical trial landscape. Alzheimer's Disease Overview Alzheimer's disease (AD) is a slowly progressive brain disease that manifests itself many years before symptoms appear. It is the leading cause of dementia, accounting for 60% to 80% of cases. The accumulation of the protein fragment beta-amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons are the hallmark pathologies of Alzheimer's disease. Alzheimer's disease is a progressive disease, so the symptoms worsen over time. Memory loss is a key feature, and it is often one of the first Alzheimer's disease symptoms to appear. The other Alzheimer's disease symptoms include cognitive deficits, problems with recognition, problems with spatial awareness, and others. A thorough clinical evaluation, a detailed patient history, and various specialized tests are used to make an Alzheimer's disease diagnosis. Clinical diagnosis, which is usually made during the early stages of the disease, lumbar puncture, and imaging studies are all methods of diagnosing Alzheimer's disease. Treatment for Alzheimer's disease includes options that may alleviate symptoms and improve quality of life. To treat cognitive symptoms, the FDA has approved two types of medications to treat cognitive symptoms: cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda). Other non-pharmacological therapies are also used to maintain or improve cognitive function, daily living ability, or overall quality of life. Find out more about drugs for Alzheimer's disease @ New Alzheimer's Disease Drugs A snapshot of the Alzheimer's Disease Pipeline Drugs mentioned in the report: Learn more about the emerging Alzheimer's disease pipeline therapies @ Alzheimer's Disease Clinical Trials Alzheimer's Disease Therapeutics Assessment The Alzheimer's disease pipeline report proffers an integral view of Alzheimer's disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Alzheimer's Disease Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Amyloid beta-protein inhibitors, Inflammation mediator inhibitors, Immunostimulants, Tumour necrosis factor alpha inhibitors, Microfilament protein modulators, Angiogenesis inhibitors, Colony stimulating factor inhibitors, Coronavirus-3C-like-proteinase inhibitors, Endopeptidase Clp inhibitors, Focal adhesion protein-tyrosine kinase inhibitors, Lyn protein-tyrosine kinase inhibitors, Macrophage colony-stimulating factor receptor modulators, Mast cell inhibitors, Platelet-derived growth factor receptor antagonists, Protein tyrosine kinase inhibitors, Proto oncogene protein c-kit inhibitors, Proto-oncogene protein c-fyn modulators, Type 3 fibroblast growth factor receptor antagonists Key Alzheimer's Disease Companies: Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd., Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others. Key Alzheimer's Disease Pipeline Therapies: ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002,CMS121, LX1001, TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx, Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916, AR1001, ORY-2001, LY3372689, MW150, EX039, SLS-005, Seltorexant, Donanemab, SHR-1707, REM0046127, ALZ-101, VT301, NE3107, PRX005, MK-6240, and others. Dive deep into rich insights for new drugs for Alzheimer's disease treatment; visit @ Alzheimer's Disease Medications Table of Contents For further information on the Alzheimer's disease pipeline therapeutics, reach out @ Alzheimer's Disease Drug Treatment Related Reports Alzheimer's Disease Epidemiology Alzheimer's Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Alzheimer's disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Alzheimer's Disease Market Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies including AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, among others. Neurostimulation Devices Market Neurostimulation Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurostimulation devices companies, including Medtronic PLC, Cyberonics, Boston Scientific Corporation, Abbott Laboratories, among others. Deep Brain Stimulation Devices Market Deep Brain Stimulation Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key deep brain stimulation devices companies, including Abbott, Medtronic, Boston Scientific Corporation, ALEVA NEUROTHERAPEUTICS SA., Newronika S.p.A., among others. Neuromodulation Devices Market Neuromodulation Devices Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neuromodulation devices companies, including Medtronic, Boston Scientific Corporation, Abbott, LivaNova, NeuroSigma, NEVRO CORP., among others. Neuroprosthetics Market Neuroprosthetics Market Insight, Competitive Landscape, and Market Forecast – 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neuroprosthetics companies, including Medtronic, Cochlear Ltd., Abbott, Boston Scientific Corporation, among others. Other Trending Reports Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

Clinical ResultPhase 3Phase 1Acquisition

100 Deals associated with TB-006

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 2	US	TrueBinding, Inc.Startup	14 Sep 2022
Acute Ischemic Stroke	Phase 2	US	TrueBinding, Inc.Startup	01 Apr 2022
COVID-19	Phase 1	-	TrueBinding, Inc.Startup	01 Jun 2021
Stroke	Phase 1	-	TrueBinding, Inc.Startup	-
Autism Spectrum Disorder	IND Application	US	TrueBinding, Inc.Startup	13 Sep 2024
Parkinson Disease	IND Application	US	TrueBinding, Inc.Startup	13 Sep 2024
Amyotrophic Lateral Sclerosis	Preclinical	US	TrueBinding, Inc.Startup	13 Sep 2024
Glioblastoma	Preclinical	US	TrueBinding, Inc.Startup	13 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05074498 (CTgov)	Phase 1/2	Alzheimer Disease	154	Placebo (Part 1: Placebo)	qguvfqdaev(ekhgqbvjox) = gdjemiqbse ueqzuabgvm (thyqfjtmhr, ilvfxrdnpk - khspeqkfqi) View more	-	18 Nov 2023
				Placebo (Part 2: Placebo)	rftafdkjyj(ysnioirhrd) = xhtzupyjfi ngtluvqlxb (cglzgevjqw, jorlbjbmrc - rduudfnbya) View more
NCT05074498 (Corporate Publications) Manual	Phase 1/2	Alzheimer Disease	140	TB006	fgbbzwilpn(eoxwzcugpg) = mzmsrumcup eyiylzbrdr (yzfwewrsus ) View more	Positive	18 Nov 2022
				Placebo	fgbbzwilpn(eoxwzcugpg) = ueobhpnwio eyiylzbrdr (yzfwewrsus ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis